Sun Pharmaceutical Industries Ltd. - Moneycontrol Sun Pharma Standalone December 2024 Net Sales at Rs 6,191 81 crore, up 22 04% Y-o-Y 31 01 2025 Sun Pharma Q3 net profit rises 15% to Rs 2,903 4 crore, meets estimate; Rs 10 5 dividend declared
Creating Lasting Value - Sun Pharma Gross margin= (Net Sales –Material Cost) Net Sales * 100 #Top 9 Indian Pharma companies include Cipla, Dr Reddy’s, Aurobindo, Zydus Lifesciences, Torrent, Alkem Labs, Lupin, Ipca and Glenmark Best-in-class profitability
Sun Pharma vs Divi’s Lab vs Dr. Reddy’s Lab vs Cipla Sun Pharma recently reported its financial results, showing a notable increase in its net profit and revenue For the quarter ending in December 2023, Sun Pharma recorded a consolidated profit after tax of 25 24 billion rupees, exceeding analysts’ expectations
Sun Pharma To Dr. Reddys Q4 Preview: Indian Pharmas To See Strong Q4 . . . As Indian pharmaceuticals commence announcement of fourth quarter earnings, the aggregate picture suggests a 16% year-on-year sales growth for a cohort of key players — Sun Pharmaceutical Industries Ltd , Cipla Ltd , Dr Reddy's Laboratories Ltd, Torrent Pharma, and JB Chemicals Pharmaceuticals
FINANCIAL PERFORMANCE ANALYIS OF CIPLA SUN PHARMA- A COMPARITIVE STUDY performance of gross profit and operating profit While measuring the gross profit of SUN PHARMA the GP margin was at 94 92% whereas for CIPLA it is 75 06%, this is mainly due to increase in overall cost, however the ROCE of SUN PHARMA is 13 15% in 2021, whereas it 5 4% for CIPLA
Sun Pharma Q4 FY25: Profit May Rise 18% YoY to ₹3,070 Cr - Value Research Sun Pharma remains the largest among peers, both in terms of revenue and profit Dr Reddy's shows the fastest revenue growth due to biosimilar launches and portfolio gains Cipla sees moderate growth driven by strength in India and South Africa
Cipla Vs Dr. Reddy’s Laboratories – Financials, Future Plans More Upon comparing Revenue Profit figures Dr Reddy’s significantly outperforms Cipla On a 5 5-year term period, Cipla is able to maintain a Revenue growth of 9% CAGR while Dr Reddy maintains 13% CAGR Profitability of Cipla Dr Reddy’s grew by 16% and 23% on a 5 Year CAGR
Sun Pharma Q4 Results: Profit misses estimate, revenue up 8% . . . - CNBCTV18 Sun Pharma posted an 8 1% revenue rise in Q4, but profit fell 19% EBITDA margins expanded sharply, and the company announced a ₹5 50 final dividend Sun Pharmaceutical Industries Ltd India’s largest drugmaker, reported a mixed set of numbers for the quarter ended March 2025